Buchumschlag

Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors

The epidermal growth factor receptor (EGFR) is involved in development and progression of some gastrointestinal cancers, and is targeted by monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) used to treat these conditions. Targeted agents are generally better tolerated than conventio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: Hofheinz, Ralf-Dieter (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 11 April 2017
In: Critical reviews in oncology, hematology
Year: 2017, Jahrgang: 114, Pages: 102-113
ISSN:1879-0461
DOI:10.1016/j.critrevonc.2017.03.032
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1016/j.critrevonc.2017.03.032
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1040842816303869
Volltext
Verfasserangaben:Ralf-Dieter Hofheinz, Siegfried Segaert, María José Safont, Gaston Demonty, Hans Prenen

MARC

LEADER 00000caa a2200000 c 4500
001 1580053211
003 DE-627
005 20220814220228.0
007 cr uuu---uuuuu
008 180815s2017 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.critrevonc.2017.03.032  |2 doi 
035 |a (DE-627)1580053211 
035 |a (DE-576)510053211 
035 |a (DE-599)BSZ510053211 
035 |a (OCoLC)1341016903 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Hofheinz, Ralf-Dieter  |d 1969-  |e VerfasserIn  |0 (DE-588)121917517  |0 (DE-627)08161876X  |0 (DE-576)292991568  |4 aut 
245 1 0 |a Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors  |c Ralf-Dieter Hofheinz, Siegfried Segaert, María José Safont, Gaston Demonty, Hans Prenen 
264 1 |c 11 April 2017 
300 |a 12 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Available online 11 April 2017 
500 |a Gesehen am 15.08.2018 
520 |a The epidermal growth factor receptor (EGFR) is involved in development and progression of some gastrointestinal cancers, and is targeted by monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) used to treat these conditions. Targeted agents are generally better tolerated than conventional chemotherapy, but have characteristic toxicities that can affect adherence, dosing, and outcomes. Skin conditions are the most common toxicities associated with EGFR inhibitors, particularly papulopustular rash. Other common toxicities include mucosal toxicity, electrolyte imbalances (notably hypomagnesaemia), and diarrhoea, while the chimaeric mAb cetuximab is also associated with increased risk of infusion reactions. With appropriate prophylaxis, the incidence and severity of these events can be reduced, while management strategies tailored to the patient and the degree of toxicity can help to ensure continuation of anti-cancer therapy. Here, we review the main toxicities associated with EGFR-inhibiting mAbs and TKIs in patients with gastrointestinal cancers, and provide recommendations for prophylaxis and treatment. 
650 4 |a Cetuximab 
650 4 |a EGFR 
650 4 |a Gastrointestinal cancer 
650 4 |a Monoclonal antibodies 
650 4 |a Panitumumab 
650 4 |a TKIs 
650 4 |a Toxicity 
773 0 8 |i Enthalten in  |t Critical reviews in oncology, hematology  |d Amsterdam [u.a.] : Elsevier Science, 1983  |g 114(2017), Seite 102-113  |h Online-Ressource  |w (DE-627)320649024  |w (DE-600)2025731-4  |w (DE-576)094108137  |x 1879-0461  |7 nnas  |a Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors 
773 1 8 |g volume:114  |g year:2017  |g pages:102-113  |g extent:12  |a Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors 
856 4 0 |u http://dx.doi.org/10.1016/j.critrevonc.2017.03.032  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S1040842816303869  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20180815 
993 |a Article 
994 |a 2017 
998 |g 121917517  |a Hofheinz, Ralf-Dieter  |m 121917517:Hofheinz, Ralf-Dieter  |d 60000  |d 65500  |e 60000PH121917517  |e 65500PH121917517  |k 0/60000/  |k 1/60000/65500/  |p 1  |x j 
999 |a KXP-PPN1580053211  |e 3022374984 
BIB |a Y 
SER |a journal 
JSO |a {"title":[{"title_sort":"Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors","title":"Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors"}],"language":["eng"],"person":[{"family":"Hofheinz","given":"Ralf-Dieter","role":"aut","display":"Hofheinz, Ralf-Dieter"}],"name":{"displayForm":["Ralf-Dieter Hofheinz, Siegfried Segaert, María José Safont, Gaston Demonty, Hans Prenen"]},"id":{"doi":["10.1016/j.critrevonc.2017.03.032"],"eki":["1580053211"]},"physDesc":[{"extent":"12 S."}],"relHost":[{"pubHistory":["1.1983/84 -"],"language":["eng"],"part":{"text":"114(2017), Seite 102-113","year":"2017","volume":"114","pages":"102-113","extent":"12"},"title":[{"title_sort":"Critical reviews in oncology, hematology","title":"Critical reviews in oncology, hematology"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedDisp":"1983-","publisher":"Elsevier Science","dateIssuedKey":"1983","publisherPlace":"Amsterdam [u.a.]"}],"recId":"320649024","note":["Gesehen am 04.02.20"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2025731-4"],"issn":["1879-0461"],"eki":["320649024"]},"disp":"Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitorsCritical reviews in oncology, hematology"}],"note":["Available online 11 April 2017","Gesehen am 15.08.2018"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"11 April 2017"}],"recId":"1580053211"} 
SRT |a HOFHEINZRAMANAGEMENT1120 

Ähnliche Einträge